Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model.

Journal of medicinal chemistry - 22 Apr 2021

Shen Sida, Picci Cristina, Ustinova Kseniya, Benoy Veronick, Kutil Zsófia, Zhang Guiping, Tavares Maurício T, Pavlíček Jiří, Zimprich Chad A, Robers Matthew B, Van Den Bosch Ludo, Bařinka Cyril, Langley Brett, Kozikowski Alan P

Abstract excerpt

Histone deacetylase 6 (HDAC6) is a promising therapeutic target for the treatment of neurodegenerative disorders. SW-100 (1a), a phenylhydroxamate-based HDAC6 inhibitor (HDAC6i) bearing a tetrahydroquinoline (THQ) capping group, is a highly potent and selective HDAC6i that was shown to be effective in mouse models of Fragile X syndrome and Charcot-Marie-Tooth disease type 2A (CMT2A). In this study, we report the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetylation
Share to Benzamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Charcot-Marie-Tooth Disease

Share to Half-Life

Share to Histone Deacetylase Inhibitors

Share to Molecular Docking Simulation

Share to Quinolines

Share to Tubulin

Source

Identifiers

PMID: 33830764
DOI: 10.1021/acs.jmedchem.0c02210

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model.PMID 33830764Read ↗

Bicyclic-Capped Histone Deacetylase 6 Inhibitors with Improved Activity in a Model of Axonal Charcot-Marie-Tooth Disease.Semantic proximity Read ↗

A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective InhibitorsSemantic proximity Read ↗

Drug Discovery for Histone Deacetylase Inhibition: Past, Present and Future of Zinc-Binding GroupsSemantic proximity Read ↗

HDAC6 inhibition partially alleviates mitochondrial trafficking defects and restores motor function in human motor neuron and zebrafish models of Charcot-Marie-Tooth Disease Type 2ASemantic proximity Read ↗

Drug Discovery for Histone Deacetylase Inhibition: Past, Present and Future of Zinc-Binding GroupsSemantic proximity Read ↗

MeFluHyA: a novel fluorescent screening tool for high-throughput identification of HDAC6-selective inhibitorsSemantic proximity Read ↗

Medicinal chemistry advances in targeting class I histone deacetylasesSemantic proximity Read ↗

The Effect of Various Zinc Binding Groups on Inhibition of Histone Deacetylases 1–11Semantic proximity Read ↗

Discovery of a Potent SARM1 Base-Exchange Inhibitor with In Vivo EfficacySemantic proximity Read ↗

Putting the ‘HAT’ back on survival signalling: the promises and challenges of HDAC inhibition in the treatment of neurological conditionsSemantic proximity Read ↗

Structural and in Vivo Characterization of Tubastatin A, a Widely Used Histone Deacetylase 6 InhibitorSemantic proximity Read ↗

Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.